RICARDO-UK-LTD
30.3.2021 01:03:06 CEST | Business Wire | Press release
Cranfield Aerospace Solutions (CAeS) - the UK SME leading the Project Fresson consortium - announces it will exploit recent advances in hydrogen fuel cell technology to develop a commercially viable, retrofit powertrain solution for the nine-passenger Britten-Norman Islander aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005667/en/
Following a rigorous assessment of hydrogen technology innovators, CAeS is delighted to welcome Ricardo UK Ltd and Innovatus Technologies Ltd to the Fresson consortium. Ricardo UK Ltd brings expertise in fuel cell system development and Innovatus Technologies Ltd brings their innovative Scottish Hydrogen Fuel Tank (SHyFT) technology.
Steve Dyke, Managing Director Ricardo Automotive and Industrial EMEA Division said: “We are proud to join the Cranfield Aerospace Solutions consortium to play our part in helping to reduce the carbon footprint for commercial air passengers. We are already working on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. Our work for the Fresson consortium will enable us to consolidate and grow our hydrogen fuel cell and propulsion capability, so that Ricardo can achieve its ambition of becoming a world-leader in hydrogen and fuel cell services and solutions and help accelerate net zero transportation.”
Innovatus Technologies Ltd leads the field in next generation ultralightweight hydrogen tank design exploiting patented cellular core composite techniques. This is critical to the successful integration and exploitation of hydrogen fuel cell power systems in applications across aerospace, automotive, industrial, and marine sectors.
Ruan Swart, Chief Executive Officer Innovatus Technologies Ltd said: ““We are proud in being selected to join the Cranfield Aerospace Solutions, ‘Project Fresson’, consortium. Our unique and innovative SHyFT solution is game-changing in bringing zero carbon fuel cell energy to commercial reality in the transport sector. Project Fresson showcases important Scottish innovation and next generation hydrogen tank manufacturing in the UK.”
Project Fresson will deliver an emissions-free (zero CO2 ), hydrogen-fuel-cell-powered flying demonstrator by September 2022. Having completed a comprehensive evaluation of technologies and configurations for sustainable aircraft propulsion, the Fresson team concluded that hydrogen fuel cell technology is the optimum solution to meet environmental, regulatory and operational requirements for this size of aircraft, enabling zero carbon emissions and reducing operating costs. This has presented the Fresson consortium, which includes Britten-Norman and Cranfield University, with an opportunity to deliver an enhanced technology programme that surpasses the original demonstrator concept.
Paul Hutton, Chief Executive Officer, Cranfield Aerospace Solutions said: “This is incredibly important for the Project Fresson Team but also for everyone else around the world interested in zero emissions flight. This project can deliver the world’s first truly “green” passenger carrying airline services. The whole team is proud of what Project Fresson has achieved so far and excited about what is to come. I am very thankful for the support of the ATI and our investors for making this ground-breaking work a reality.”
Jenny Kavanagh, Chief Strategy Officer, Cranfield Aerospace Solutions added: “Covid-19 has caused the biggest crisis in aviation’s history. It’s important that, as the sector builds back better, it does so with sustainability at its heart. Project Fresson is more than just a technology demonstrator; it has one focus above all others: real operational and commercial viability.”
Project Fresson is supported by the ATI Programme, a joint Government and industry investment to maintain and grow the UK’s competitive position in civil aerospace design and manufacture. The programme, delivered through a partnership between the Aerospace Technology Institute (ATI), Department for Business, Energy & Industrial Strategy (BEIS) and Innovate UK, addresses technology, capability and supply chain challenges.
As a result of these changes, there is now no longer a need for the Rolls-Royce element of the aircraft programme. It is therefore Rolls-Royce’s intention to withdraw from Project Fresson and the consortium is going through the necessary steps for this to happen. We thank Rolls-Royce for its contribution to Project Fresson and wish its team well. Rolls-Royce will continue to actively research the use of hydrogen in aviation and this decision in no way reflects its overall view of hydrogen as a potential technology.
Ends
Notes to editors
- To follow the progress of Project Fresson, visit the microsite: www.projectfresson.uk or follow on Twitter @projectfresson.
- Cranfield Aerospace Solutions (CAeS) is an aerospace market leader in rapid prototyping of new aerospace concepts, modifications to existing aerospace platforms and integration of cutting-edge technologies to meet the most challenging issues facing the industry today. CAeS is the wholly owned commercial arm of Cranfield University. Visit: www.cranfieldaerospace.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005667/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom